SLC9A6 and metabolic dysfunction-associated steatotic liver disease: The clinical targeting of circ‐SLC9A6 and SLC9A6‐126aa in NAFLD may provide important insights into potential interventions for NAFLD‐related diseases such as type 2 diabetes, sarcopenia, and aging.34, 35